Recent clinical trials have demonstrated that pre-exposure prophylaxis (PrEP) may prevent HIV infection in a significant number of HIV-1 negative individuals in venerable populations. Sustained-release, intravaginal delivery of one or move antiretroviral (ARV) drugs or other anti-HIV agents holds promise for effective PrEP with improved adherence over daily or coitally-dependent dosing regimens. We have developed a novel IVR platform (“pod-IVR”) and applied it to intravaginal delivery of combinations of drugs with widely varying physicochemical properties, including small-molecule ARV agents, hormones, peptides, DNA, monoclonal antibodies, and probiotic bacteria. This talk will focus on two applications: (1) pre-clinical development and Phase 1 clinical trial of a pod-IVR delivering tenofovir disoproxil fumarate and emtricitabine, the ARV combination in Truvada, the only FDA-approved product for oral PrEP; and (2) development of a pod-IVR delivering the anti-HIV monoclonal antibody VRC01 and evaluation of pharmacokinetics and preliminary safety in a rhesus macaque model.
Date:April 08, 2016
Time: 12:00 PM - 01:00 PM (PT)
Location:Argyros Auditorium, Arnold and Mabel Beckman Building
Presenters:John A. Moss, Ph.D. Senior Faculty, Inorganic & Environmental Chemistry Oak Crest Institute of Science
Sponsor(s):Beckman Research Institute Seminar Series Department of Molecular Medicine